AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05319106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell preparation combined with silver ion dressing
Description: The dosage range of each cm2 ulcer wound is (1～5)×10\^6. The dosage of human umbilical cord mesenchymal stem cells for the second treatment is determined according to the severity of the ulcer. Each patient is treated for 2 consecutive times, and the interval between each treatment is 3 days.
Study NCT05319106 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: silver ion dressing
Description: fter wound debridement, a silver ion dressing suitable for the size of the wound was cut and covered on the wound bed. Sterile gauze was covered on the silver ion dressing and fixed with adhesive tape.
Study NCT06484270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation based safety mobilization program
Description: Nurse participants experienced safe patient mobilization with a simulation-based learning method with a standardized patient for 4 weeks.~Patient participants were mobilized safely under the supervision of a nurse and the care results were measured.
Study NCT06016010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL
Description: 500mg of Achyranthis Radix Extract
Study NCT06016010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: USL Placebo
Description: USL Placebo
Study NCT06016010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL Placebo
Description: USL Placebo
Study NCT05908214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wide pulse high frequency neuromuscular electrical stimulation training
Description: Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks
Study NCT04735744 — intervention group
Intervention type: OTHER
Intervention: Patients recovering from COVID19 receive usual care by allied health professionals
Description: We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
Study NCT05310734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad Topical
Description: A topical suspension indicated for the treatment of scabies is used for this PK and Safety Study
Study NCT05769361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UNST
Description: Strength and balance training using different destabilizing devices
Study NCT05769361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ST
Description: Strength and balance training over firm surfaces
Study NCT04899245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BinaxNOW Rapid Antigen System
Description: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Study NCT06244706 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Opioid drug + CNS-acting add-on drug
Description: Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment).
Study NCT06064006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111
Description: NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
Study NCT06064006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NNC0487-0111
Description: NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
Study NCT06064006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0487-0111)
Description: Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
Study NCT06064006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0487-0111)
Description: Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
Study NCT05835011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine/Cedazuridine
Description: Oral FDC tablets administration
Study NCT05835011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: IV administration
Study NCT05326178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General information about depression
Description: Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression.
Study NCT05650619 — intervention group
Intervention type: OTHER
Intervention: Biospecimen collection
Description: Specimens that may be collected include urine, blood, saliva, kidney tissue, etc. Biospecimens will be collected to establish the RESOLVE biobank.
Study NCT05650619 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection for all groups
Study NCT06049186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRD
Description: During the initial 8 weeks of the trial, polycystic ovary syndrome (PCOS) patients are instructed to follow a diet of 1200 to 1500 kcal per day supervised by dietitians. The CRD includes a combination of 40 to 55% of calories from carbohydrates, 15 to 20% from protein, and 20 to 30% from fat; this regimen represented approximately 75% of the participants' daily caloric intake at baseline. All the participants receive dietary counseling daily during the trial.
Study NCT06049186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: After randomization, patients entering the metformin group will be given 1500 mg daily (bid/tid) metformin and regular diets as control. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
Study NCT05452876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABCp
Description: Intervention is a care pathway that helps primary care physicians categorize back pain patients with each category having preferred interventions.
Study NCT05137067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)
Description: Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
Study NCT05137067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
Description: Placebo
Study NCT05137067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Description: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Study NCT05223647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: 30Gy/10 fractions thoracic radiotherapy given between 2nd and 3rd course of chemo-immunotherapy.
Study NCT05223647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-immunotherapy
Description: Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
Study NCT05223647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy
Description: Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
Study NCT05626673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prayer app
Description: Participants will be given the Pray.com app and directed to use it daily.
Study NCT05601323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suizenji
Description: HIFU treatment
Study NCT05601323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nal-IRI/FL
Description: Nanoliposomal irinotecan, Fluorouracil, Levofolinate
Study NCT05601323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-IRI/FL
Description: Nanoliposomal irinotecan, Fluorouracil, Levofolinate
Study NCT05601323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
Study NCT05601323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
Study NCT05601323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gem/nab-PTX
Description: Gemcitabine, nab-Paclitaxel
Study NCT05601323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem/nab-PTX
Description: Gemcitabine, nab-Paclitaxel
Study NCT05452876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard of care treatment
Study NCT05272852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FARAPULSE™ Pulsed Field Ablation System Plus
Description: Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
Study NCT04805749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy: osteopathy
Description: Osteopathic protocol applied at week 0, 1, 2 and 3:~1. Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine.~2. Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum.~3. Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia.~4. Cranial osteopathy techniques to address the vagus parasympathetic nerves.
Study NCT05108649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Messaging
Description: After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session or delayed control messaging at the final study session.
Study NCT05108649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette Condition
Description: After completing a 7-day period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content (RNC) cigarettes or normal nicotine content (NNC) cigarettes.
Study NCT04919980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovalve MR system
Description: Innovalve MR system
Study NCT06177990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver as Navigator: Develop Skills Online (CAN-DO) program
Description: Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~* The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~* The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~* The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively.
Study NCT06177990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver as Navigator: Develop Skills Online (CAN-DO) program
Description: Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~* The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~* The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~* The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively.
Study NCT06177990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living online course
Description: Online program for dementia family caregivers about Healthy Living for the first 4 months post-randomization.
Study NCT06246955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention: Group Therapy Session
Description: Attend virtual group therapy sessions
Study NCT06246955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study NCT06144424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral EP262
Description: Once daily
Study NCT06144424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once Daily
Study NCT03636724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-intervention
Description: The 10-week e-health intervention will target HAPA-based social-cognitive variables of PA and FVI. Particularly, Week 1: risk perception and outcome expectancies; Week 2: goal setting; Week 3: development of action plans; Week 4: revision and adjustment of previous action plans; Week 5: development of coping plans; Week 6: revision and adjustment of previous coping plans; Week 7: development of perceived social support; Week 8: revision and adjustment of previous social support. Week 9-10: self-monitoring. Self-efficacy will be a fixed intervention variable involved from week 2 to week 10. Additionally, some behaviour change techniques will be employed in the intervention in order to facilitate the implementation and maintenance of behaviour.
Study NCT06074796 — intervention group
Intervention type: BEHAVIORAL
Intervention: No intervention.
Description: No intervention. This is a retrospective study. Data will have been collected in routine consultations as part of the transition process for transgender patients.~Description of the collected informations : gender of destination, BMI, siblings, children, moral, previous hormone therapy, when the project was born, change of marital status desired or carried out, ALD status, psychiatric assessment, desire for future care for the transition course. Desire to preserve erectile function, parenthood desire, couple projections, type of couple, cryopreservation desired, done or not, desire of pregnancy, ultrasound count of antral follicles, initial hormone assays and tests : BMD, pelvic ultrasound? Data relating to stimulation and ovarian puncture and sperm collection.
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Alectinib
Description: ALK fusion or mutations, Mutations or amplification in any of the following: RET
Study NCT05946447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The gastric antrum will be scanned using ultrasound.
Study NCT04658537 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
Study NCT04658537 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab
Description: MSI high status by any method Or Any mutation in any of these genes:~MLH1 or MSH2 or MSH6 or PMS2 or EPCAM Or Any of the following mutations in POLE: R150X, P286R, P286H, S297F, Y298fs, F367S, V411, L424V, P436R, S459F, R665W, L698fs, R762W, R1519C, R1826W, D316H, D316G, R409W, L474P Or Any of the following mutations in POLD1: P112fs, A930fs, S478N Or Any mutation in the following: POLE not listed above, POLD1 not listed above, POLD2, POLD3, POLD4, POLQ or PRKDC Or Any loss of function mutations in BRCA1, BRCA2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1, RFC2, RFC3, RFC4, RFC5, PCNA, RPA1, PRA2, PRA3, PRA4, or SSBP1 High tumor mutational burden decided by KOSMOS-II MTB (TMB ≥20/Mb in local NGS or if 10-20/Mb, confirmed by central NGS te sting)
Study NCT05934994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
Study NCT06271616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Erlotinib
Description: EGFR Exon 19 deletions in the region E746_E759;~Any of the following EGFR mutations:~E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab + Pertuzumab
Description: ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab emtansine
Description: ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775_G776insSVMA, A775_G776insYVMA (i.e.,Y772_A775dup,M774_A775insAYVME 770delinsEAYVM), G776_V777 > AVCV, G776_V777 > AVGCV, G776_V777 > VCV, G776_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777_G778insC, V777L, V777M, G778_Y779insGSP, P780_Y781insGSP (i.e.,G778_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Vemurafenib
Description: BRAF_V600E/D/K/R mutations
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab + Erlotinib
Description: FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Entrectinib
Description: ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board
Study NCT05525858 — intervention group
Intervention type: DRUG
Intervention: Pralsetinib
Description: RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
Study NCT05475366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC
Description: Formalin-Fixed Paraffin-Embedded (FFPE) samples will be centralized in which nucleic acids extraction (DNA+RNA) and FFPE-compatible RNA-sequencing will be performed in real-time (≤28 days). RNAseq reads will be processed and all 5 transcriptomic signatures will be applied for prediction of response to 5FU, oxaliplatin, irinotecan, gemcitabine and taxane. In addition, biomarkers status will be obtained for all patients as part of good clinical practice.
Study NCT05475366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers of tumor signatures (translational studies)
Description: Blood (serum and plasma) will be drawn at baseline, week 8, and tumor progression in order to look for surrogate biomarkers of tumor signatures in liquid biopsy
Study NCT06070870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Navigation will address the following 4 domains of barriers to screening:~* Individual~* Organizational~* Economic~* Sociocultural At the first visit, navigators will assess the participant's barriers in each of these domains. Any follow-up visits, if necessary, will be used to help the participant overcome these barriers to screening
Study NCT06271616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT05011058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat in combination with valganciclovir
Description: Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Other name: VRx-3996~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles